Photo from Pashtoon Kasi/X
Apr 3, 2024, 06:35
Pashtoon Kasi: ctDNA kinetics is going to be an important variable to look at in patients getting novel immunotherapy drugs like the BOT/BAL on our NEST trial
Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X/Twitter:
”ctDNA kineticsis going to be an important variable to look at in patients getting novel immunotherapy drugs like the BOT/BAL on our NEST trial. The longer you let it brew, the deeper the drop eventual clearance. 100 post-operation. March is Colorectal Cancer Awareness Month.”
Source: Pashtoon Kasi/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56
Nov 13, 2024, 15:46